ReviewVascular health and risk management2015
Assessing the risk of recurrent venous thromboembolism--a practical approach.
Review in Vascular health and risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Measurement of Active Thrombin Bound to Circulating D-Dimers as a Sensitive Biomarker for Prothrombotic Conditions.Journal of clinical laboratory analysis · 2026Article
- Proteomic Biomarkers in VTE: From Discovery to Clinical Translation.Journal of clinical medicine · 2026Review
- Predictors of Secondary Pulmonary Hypertension-Related Hospitalizations and Subsequent Mortality in Adults with Obstructive Sleep Apnea.Diseases (Basel, Switzerland) · 2026Article
- Plasma Level of Human Epididymis Protein 4 and Risk of Recurrence after First Venous Thromboembolism: The HUNT Study.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Development of a MassARRAY Genotyping Platform and Its Clinical Application for Venous Thromboembolism Risk Assessment in Thai Patients.Medical sciences (Basel, Switzerland) · 2025Article
- Safety and Efficacy of Rivaroxaban Versus Warfarin in Cerebral Venous Thrombosis: A Comprehensive Meta-Analysis.Neurology international · 2025Review
- Point-of-Care Ultrasound in the Diagnosis of Hematoma Mimicking Deep Vein Thrombosis: A Case Report.Cureus · 2025Article
- Direct Oral anticoagulants in pulmonary thromboembolism therapy: the generalization-individualization dilemma and the path to risk stratification-a perspective.Frontiers in medicine · 2025Article
- Hand grip strength in venous thromboembolism: risk of recurrence and mortality.Research and practice in thrombosis and haemostasis · 2023Article
- Health Literacy and Treatment Satisfaction Among Patients with Venous Thromboembolism.Journal of general internal medicine · 2023Article
- Implementation of a Patient Questionnaire in Community Pharmacies to Improve Care for Patients Using Combined Antithrombotic Therapy: A Qualitative Study.Pharmacy (Basel, Switzerland) · 2023Article
- Exploring the Clinical Efficacy of Venous Thromboembolism Management in Saudi Arabian Hospitals: An Insight into Patient Outcomes.Journal of personalized medicine · 2023Article
- Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism.Clinical and translational science · 2023Article
- Catheter-Directed Interventions for the Treatment of Lower Extremity Deep Vein Thrombosis.Life (Basel, Switzerland) · 2022Review
- Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France.Advances in therapy · 2022Article
- Joint Guideline on Venous Thromboembolism - 2022.Arquivos brasileiros de cardiologia · 2022Article
- The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases.Advances in therapy · 2022Article
- Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease.Advances in therapy · 2022Article
- Clinical epidemiology of venous thromboembolic disease: An institutional registry.Frontiers in cardiovascular medicine · 2022Article
- Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study.European journal of clinical pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent venous thromboembolism (VTE) is associated with increased morbidity and mortality. This risk is lowered by anticoagulation, with a large effect in the initial phase following the venous thromboembolic event, and with a smaller effect in terms of secondary prevention of recurrence when extended anticoagulation is performed. On the other hand, extended anticoagulation is associated with an increased risk of major bleeding and thus leads to morbidity and mortality. Therefore, it is necessary to assess the risk of recurrence for VTE on an individual basis, and a recommendation for secondary prophylaxis should be specifically based on risk calculation of recurrence of VTE and bleeding. In this review, we provide a comprehensive summary of relevant risk factors for recurrent VTE and a practical approach for assessing the risk of recurrence in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.